Jutta Steinseifer

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

José Baselga, Peter van Dam, Alexey Manikhas et al. · Journal of Clinical Oncology · 2009 · 658 citations

Medicine, Oncology, Pharmacology +17

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

Luca Gianni, W. Eiermann, Aňa Lluch et al. · The Lancet Oncology · 2014 · 491 citations

Medicine, Oncology, Breast Oncology +16

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

Evandro de Azambuja, Marion Procter, Dirk J. van Veldhuisen et al. · Journal of Clinical Oncology · 2014 · 233 citations · Full text

Medicine, Cardiology, Oncology +17

Role of Troponins I and T and <i>N</i>-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy

Dimitrios Zardavas, Thomas Suter, Dirk J. van Veldhuisen et al. · Journal of Clinical Oncology · 2017 · 165 citations

Medicine, Cardiology, Oncology +17

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics

Ahmad Awada, Fátima Cardoso, Christel Fontaine et al. · European Journal of Cancer · 2007 · 152 citations

Medicine, Oncology, Pharmacology +14